JBM (Healthcare) Ltd. (2161) AI Stock Analysis

• Market Cap: HK$2.25B
• Dividend Yield: 3.49%
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): 11.4
• Beta (1Y): 0.35
• Revenue Growth: 18.06%
• EPS Growth: 80.57%
• Country: HK
• Employees: 279
• Sector: Healthcare
• Sector Strength: 58
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.13
• Shares Outstanding: 822,000,000
• 10 Day Avg. Volume: 996,953
• 30 Day Avg. Volume: 1,197,023
• PEG Ratio: 0.13
• Price to Book (P/B): 0.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 6.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 79 Outperform
• Price Target: ―

JBM (Healthcare) Ltd. exhibits a strong financial performance with robust revenue and profit growth, prudent financial management, and a solid cash flow position. The technical indicators suggest a stable trend, though further momentum analysis is constrained. The stock's low P/E ratio and high dividend yield enhance its attractiveness for investors, contributing to a positive overall score. These factors collectively position the company well for future growth, providing resilience against market fluctuations.

JBM (Healthcare) Ltd. Business Overview & Revenue Model

Company Description

JBM (Healthcare) Limited, an investment holding company, develops, manufactures, markets, distributes, and sells healthcare and wellness products in Asia. The company offers consumer healthcare and proprietary Chinese medicines, such as over-the-counter medicines, and medicated and non-medicated solutions, as well as diagnostic devices; and pharmaceutical products. It is also involved in the trading, wholesaling, and retailing of Chinese medicines; trading of medical supplies and pharmaceutical products; and sale of healthcare and herbal products. The company was incorporated in 2020 and is headquartered in Kwun Tong, Hong Kong. JBM (Healthcare) Limited is a subsidiary of JBM Group (BVI) Limited.

How the Company Makes Money

JBM (Healthcare) Ltd. generates revenue primarily through the sale of its healthcare products, including medical devices, health supplements, and personal care items. The company engages in both direct sales and distribution partnerships, allowing it to reach a broader market. Additionally, JBM (Healthcare) Ltd. may leverage strategic partnerships with healthcare providers and retailers to increase its market presence and drive sales. The company's earnings are significantly influenced by its ability to innovate and introduce new products that meet the evolving needs of consumers in the healthcare industry.

JBM (Healthcare) Ltd. Financial Statement Overview

Summary

JBM (Healthcare) Ltd. demonstrates strong financial health across income, balance sheet, and cash flow metrics. The company benefits from substantial revenue and profit growth, efficient operations, and prudent financial management, resulting in a stable and profitable business trajectory. With a solid cash flow and low leverage, JBM is well-positioned for future growth and resilience against market fluctuations.

Income Statement

JBM (Healthcare) Ltd. exhibits a robust income statement with significant revenue growth at 24.62% from 2023 to 2024. The gross profit margin stands at 52.12%, indicating strong profitability. Net profit margin improved to 20.12%, showcasing efficient cost management. Both EBIT and EBITDA margins are healthy at 26.86% and 34.03%, respectively, reflecting operational efficiency.

Balance Sheet

The company maintains a solid balance sheet with a low debt-to-equity ratio of 0.14, indicating prudent leverage management. Return on equity improved to 13.44%, demonstrating effective utilization of equity capital. The equity ratio is strong at 69.89%, highlighting financial stability. The company's cash position is healthy, with an increase in cash equivalents.

Cash Flow

Cash flow performance is strong, with a free cash flow growth rate of 31.34%, underpinning robust cash generation. The operating cash flow to net income ratio is 1.47, showing excellent cash conversion. The free cash flow to net income ratio of 1.39 further indicates strong cash profitability.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
720.54M	648.41M	520.32M	406.14M	397.16M	381.54M
	Gross Profit
372.85M	338.08M	187.92M	142.30M	180.94M	190.18M
	EBIT
209.97M	174.21M	67.77M	36.36M	70.91M	51.85M
	EBITDA
241.62M	220.73M	111.40M	84.14M	114.51M	87.71M
	Net Income Common Stockholders
163.88M	130.46M	57.09M	24.62M	22.60M	41.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
189.67M	140.81M	152.27M	69.84M	94.38M	72.79M
	Total Assets
1.41B	1.39B	1.40B	1.33B	1.38B	1.37B
	Total Debt
88.72M	133.41M	180.10M	213.09M	267.92M	466.36M
	Net Debt
-66.97M	-7.40M	27.83M	143.25M	173.54M	393.57M
	Total Liabilities
342.80M	366.75M	372.10M	363.30M	434.25M	653.53M
	Stockholders Equity
1.01B	970.68M	985.51M	929.20M	904.71M	657.33M
Cash Flow		Free Cash Flow
254.39M	181.00M	137.75M	52.96M	35.97M	33.76M
	Operating Cash Flow
261.42M	191.22M	145.89M	60.01M	58.93M	38.28M
	Investing Cash Flow
12.69M	8.31M	-7.05M	-7.57M	-24.63M	43.40M
	Financing Cash Flow
-236.95M	-210.72M	-56.04M	-76.85M	-13.92M	-59.32M

JBM (Healthcare) Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.74
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2161, the sentiment is Positive. The current price of 2.74 is above the 20-day moving average (MA) of 2.53, above the 50-day MA of 2.24, and above the 200-day MA of 1.65, indicating a bullish trend. The MACD of 0.11 indicates Positive momentum. The RSI at 73.55 is Negative, neither overbought nor oversold. The STOCH value of 83.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2161.

JBM (Healthcare) Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2161	79 Outperform	HK$2.25B	11.38	19.22%	3.49%	18.06%	80.57%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
PIAIF		$126.38B	6.18		7.49%	―	―
SBMFF		$12.60B	51.81	6.14%	1.09%	―	―
CHJTF		$12.95B	19.73	13.20%	2.55%	―	―
LJUIF		$1.14B	8.07	14.96%	11.08%	―	―
LVZPF		$4.34B	12.68	14.56%	3.79%	―	―

JBM (Healthcare) Ltd. Corporate Events

JBM (Healthcare) Completes Strategic Acquisition to Expand Chinese Medicine Portfolio

JBM (Healthcare) Limited has completed the acquisition of a target company, gaining a 90% interest and making it a non-wholly owned subsidiary. This acquisition, valued at HK$171 million, is expected to enhance JBM’s portfolio by integrating the target company’s well-known product, Tin Hee Tong Tin Hee Pills, into its offerings. The move is anticipated to create synergies and expand JBM’s market reach, leveraging its experience in brand management and distribution networks.

JBM Enters 2025 License Agreement with Europharm

JBM (Healthcare) Ltd. has entered into a 2025 License Agreement with Europharm, a subsidiary of Jacobson Pharma Corporation Limited, to use a portion of a factory for three years starting from January 2025. This agreement, involving a monthly license fee of HK$218,000, is classified as a connected transaction under Hong Kong’s Listing Rules, requiring reporting and announcement but exempt from circular and independent shareholders’ approval due to its financial scale.

JBM (Healthcare) Announces Major Acquisition to Expand Market Presence

JBM (Healthcare) Limited has announced a significant acquisition of a target company, purchasing 90% of its issued share capital for HK$171,000,000. This acquisition, categorized as a discloseable transaction under Hong Kong’s Listing Rules, is expected to strengthen JBM’s market position by expanding its operational capabilities and enhancing its business portfolio.